Affimed says new data from a phase 1/2 trial of its natural killer (NK) cell engager therapy AFM13 provide further evidence of its efficacy in treating CD30+ Hodgkin and non-Hodgkin lymphom
Germany’s Affimed has signed a deal with Roche’s Genentech unit to develop cancer immunotherapies that activate natural killer cells, in a deal potentially worth more than $5 billion.
After a slow couple of years, there are signs that biotech M&A activity is coming back into vogue, and a series of small transactions announced in the last few days pr
